High AR mRNA levels were negatively linked to MYC gene overexpression (P ⍧ 8⍥10 -6 ), confirming previous in vitro studies. Our results also suggest a role of the ARA70 gene (which encodes a major AR co-activator) in the AR pathway dysregulation observed in breast cancer. This simple, rapid and semi-automated method will be useful for screening cancer patients for altered AR expression and for predicting the response to androgen therapy in AR-related cancer patients.
Introduction
The role of estrogen receptor (ER) α and the progesterone receptor (PR) in human breast cancer is well established. Considerably less is known about the functional role and clinical significance of androgen receptor (AR) expression in this setting. Biochemical and immunohistochemical studies show that AR-positive tumors are more frequent (70-90%) than ERα-positive and PR-positive tumors (60-80 and 50-70%, respectively) (1) (2) (3) (4) . Although ERα, PR and AR are frequently co-expressed in breast tumors,~10% of AR-positive tumors and, perhaps more importantly, 25% of AR-positive tumor metastases can be negative for ERα and PR (1, 5) .
Abbreviations: AR, androgen receptor; ER, estrogen receptor; PR, progesterone receptor; MPA, medroxyprogesterone acetate; SBR, Scarff-BloomRichardson.
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Androgens have been shown to regulate the proliferation of AR-positive breast cancer cell lines in culture (6) . Synthetic progestins, such as medroxyprogesterone acetate (MPA), are used as second line hormone therapy for breast cancer following tamoxifen failure (7). Birrell et al. (8) suggested that the antiproliferative effect of MPA in advanced cancer is mediated by AR. In vitro studies confirmed that MPA inhibits the proliferation of ERα-negative and PR-negative cell lines via AR (9) .
Taken together, these findings suggest that AR determination may give additional predictive information on the response to endocrine treatments in breast cancer. AR expression has mainly been studied by means of a cytosol steroid-binding assay and immunohistochemistry. Although the former measures the status and functionality of the protein, it has several methodological shortcomings (1) and is time consuming. Furthermore, it requires the use of radioactive reagents and large amounts of tumor tissue, so that it is rarely used routinely in clinical laboratories. Immunohistochemical methods suffer from a lack of inter-laboratory standardization and cannot quantify the full range of alterations. However, this method also gives information concerning the status of the protein, but above all measures alterations on an individual cell basis.
We quantified AR mRNA expression in a series of 131 patients with unilateral invasive primary breast tumors, using real-time quantitative RT-PCR assay. This recent method of nucleic acid quantification in homogeneous solutions has the potential to become a standard in terms of its performance, accuracy, sensitivity, wide dynamic range, high throughput capacity and inter-laboratory agreement, and also yields statistical confidence values (10) .
We examined the relationship between AR expression status and classical clinical and pathological parameters, including patient outcome. AR mRNA levels were interpreted according to ERα, ERβ and PR transcript levels measured using the same methodology and on the same homogeneous total RNA solutions.
We also sought relationships between AR expression and that of genes known to be altered in breast cancer (RB1, CCND1, MYC and ERBB2), as well as several major genes involved in different steps of the AR pathway dysregulation observed in prostate cancer, i.e. the ARA70 gene (which codes for a major AR co-activator) (11), two well-known AR-responsive genes in prostate cancer (PAP, coding for prostatic acid phosphatase, and PSA, coding for prostatespecific antigen) (12) and DNMT1, a DNA methyltransferase gene that is altered in tumors (13) , because loss of AR expression is associated with methylation of the AR promoter in prostate cancer cells (14) .
Materials and methods
Patients and samples
We analyzed tissue from primary breast tumors excised from 131 women treated at the Centre René Huguenin from 1977 to 1989. Tumor tissue samples of the 131 patients were collected in accordance with French regulations. The samples were examined histologically for the presence of tumor cells. A tumor sample was considered suitable for this study if the proportion of tumor cells was Ͼ60%. Immediately following surgery the tumor samples were stored in liquid nitrogen until RNA extraction.
The patients (mean age 58.2 years, range 34-91) met the following criteria: primary unilateral non-metastatic breast carcinoma on which complete clinical, histological and biological data were available; no radiotherapy or chemotherapy before surgery. The main prognostic factors are presented in Table I . The median follow-up was 8.1 years (range 1.0-15.9). Forty-seven patients relapsed (the distribution of first relapse events was as follows: 13 local and/ or regional recurrences, 30 metastases and 4 both).
Specimens of adjacent normal breast tissue from nine of the breast cancer patients and normal breast tissue from three women undergoing cosmetic breast surgery were used as sources of normal RNA.
Real time RT-PCR Theoretical basis.
Quantitative values were obtained from the threshold cycle number at which the increase in the signal associated with exponential growth of PCR products begins to be detected using PE Biosystems analysis software, according to the manufacturer's manuals.
The precise amount of total RNA added to each reaction mix (based on optical density) and its quality (i.e. lack of extensive degradation) are both difficult to assess. We therefore also quantified transcripts of the RPLP0 gene (also known as 36B4) encoding human acidic ribosomal phosphoprotein P0 as an endogenous RNA control and each sample was normalized on the basis of its RPLP0 content. The relative AR gene expression level was also normalized to a calibrator, or 1ϫ sample, consisting of a pool of normal breast tissue specimens. Final results, expressed as n-fold differences in AR gene expression relative to the RPLP0 gene and normal breast tissues (the calibrator), termed n AR , were determined in exponent as follows:
where ∆Ct values of the sample and calibrator are determined by subtracting the average Ct value of the AR gene from the average Ct value of the RPLP0 gene.
Primers and PCR consumables
Primers for the RPLP0 and target genes were chosen with the assistance of the computer programs Oligo 4.0 (National Biosciences, Plymouth, MN) and Primer Express (Perkin-Elmer Applied Biosystems, Foster City, CA). We conducted BLASTN searches against dbEST, htgs and nr (the non-redundant set of the GenBank, EMBL and DDBJ database sequences) to confirm the total gene specificity of the nucleotide sequences chosen for the primers and the absence of DNA polymorphisms. The nucleotide sequences of the primers are shown in Table II . To avoid amplification of contaminating genomic DNA, one of the two primers was placed in a different exon.
RNA extraction
Total RNA was extracted from breast specimens using the acid phenol/ guanidium method. The quality of the RNA samples was determined by electrophoresis through agarose gels and staining with ethidium bromide and the 18S and 28S RNA bands were visualized under UV light.
cDNA Synthesis RNA was reverse transcribed in a final volume of 20 µl containing 1ϫ RT buffer (500 mM each dNTP, 3 mM MgCl 2 , 75 mM KCl, 50 mM Tris-HCl, pH 8.3), 10 U RNasin RNase inhibitor (Promega, Madison, WI), 10 mM dithiothreitol, 50 U Superscript II RNase H -reverse transcriptase (Gibco BRL, Gaithersburg, MD), 1.5 mM random hexamers (Pharmacia, Uppsala, Sweden) and 1 µg total RNA. The samples were incubated at 20°C for 10 min and 42°C for 30 min and reverse transcriptase was inactivated by heating at 99°C for 5 min and cooling to 5°C for 5 min.
PCR amplification
All PCR reactions were performed using an ABI Prism 7700 Sequence Detection System (Perkin-Elmer Applied Biosystems). PCR was performed using the SYBR Green PCR Core Reagents kit (Perkin-Elmer Applied Biosystems). The thermal cycling conditions comprised an initial denaturation step at 95°C for 10 min and 50 cycles at 95°C for 15 s and 65°C for 1 min. Experiments were performed in duplicate for each data point.
Statistical analysis
Relapse-free survival was determined as the interval between diagnosis and detection of the first relapses (local and/or regional recurrences and/or metastases).
Clinical, histological and biological parameters were compared using the χ 2 test, with Yates' correction for adjustment of the continuity of the χ 2 distribution where appropriate. Differences between the two populations were judged significant at confidence levels Ͼ95% (P Ͻ 0.05). Survival distributions were estimated by the Kaplan-Meier method (15) and the significance of differences between survival rates was ascertained using the log rank test (16) .
Results
AR mRNA expression in normal breast tissues
To determine the cut-off point for altered AR expression in breast cancer tissue, the n AR value, calculated as described in Materials and methods, was determined for 12 normal breast RNA samples. As this value consistently fell between 0.70 and 1.61 (1.15 Ϯ 0.27, mean Ϯ SD), values of 2 (mean ϩ 3 SD) or more were considered to represent overexpression and values of 0.35 (mean -3 SD) or less were considered to represent underexpression of AR mRNA.
AR mRNA expression in tumor breast tissues
The 131 breast tumor RNA samples tested had a wide range of n AR values (0.008-10.3, i.e. at least 3 orders of magnitude). Compared with normal breast tissues, 69 (52.7%) tumors showed altered AR mRNA expression. Twenty-four tumors (18.3%) showed AR mRNA underexpression (n AR 0.008-0.31) and 45 (34.4%) showed overexpression (n AR 2.04-10.3). AR mRNA levels were similar to those observed in prostate tumor tissues (data not shown).
Correlation between AR mRNA levels and clinical and pathological parameters
We sought links between AR mRNA expression status and standard clinical and pathological factors in breast cancer (Table III) . Links (or trends) were found between AR gene status and age (P ϭ 0.063), menopausal status (P ϭ 0.070), Scarff-Bloom-Richardson (SBR) histopathological grade status (P ϭ 0.00083) and lymph node status (P ϭ 0.049). Patients with tumors overexpressing and/or underexpressing AR did not relapse more frequently (Table III) and did not have significantly shorter relapse-free survival after surgery (log rank test) compared with patients with tumors normally expressing AR. 
Relationship between AR mRNA levels and ERα, PR and ERβ expression status
Patients were subdivided into three equal groups with low (n ϭ 43), intermediate (n ϭ 44) and high (n ϭ 44) ERα, PR and ERβ mRNA levels. As shown in Table IV , we found a strong positive association between AR gene status and ERα (P Ͻ 10 -7 ) and PR gene (P ϭ 3ϫ10 -7 ) status and a negative association with ERβ gene status (P ϭ 0.0026). Seven (5.3%) 'ERα-negative' (low ERα mRNA expressed) tumors overexpressed AR and one (0.8%) AR-underexpressing tumor had a high ERα mRNA level. The AR and ERα mRNA status of these tumors was confirmed by repeat RT-PCR.
Relationship between AR mRNA levels and RB1, CCND1, MYC and ERBB2 expression status
The 131 tumors studied for AR expression had previously been tested for RB1, CCND1, MYC and ERBB2 mRNA expression 1523 (17-19; manuscript in preparation). We found a significant positive link between AR underexpression and RB1 underexpression (P ϭ 0.0046) and a significant negative link between AR overexpression and MYC overexpression (P ϭ 8ϫ10 -6 ), but no link between AR and CCND1 or ERBB2 mRNA status (Table V) .
Relationship between AR mRNA levels and ARA70, DNMT1, PAP and PSA expression status ARA70, DNMT1, PAP and PSA mRNA levels were analyzed in 10 AR-underexpressing and 10 AR-overexpressing breast tumors (Table VI) . For the ARA70 and DNMT1 genes patients were subdivided into two equal groups of tumors with low (n ϭ 10) and high (n ϭ 10) mRNA levels. For the PAP and PSA genes, which were very weakly expressed, patients were subdivided into tumors with detectable and no detectable mRNA molecules. We found a significant positive association between AR and ARA70 expression (P ϭ 0.0073), but no link between AR status and DNMT1, PAP or PSA mRNA levels. Moreover, the highest levels of PAP and PSA gene expression in this breast tumor series were far lower that those observed in prostate tumor tissues (data not shown).
Discussion
In this study we applied a recent RT-PCR method (10) We observed both underexpression (18% of samples) and overexpression (34%) of AR mRNA in this breast tumor series. The 24 AR-underexpressing tumors had very low levels of AR mRNA (mean of the n AR values 0.07 Ϯ 0.06) compared with the 62 tumors with normal AR expression (1.12 Ϯ 0.49), suggesting a bimodal distribution of AR expression and allowing us to use an unequivocal cut-off (n AR ϭ 0.35) to distinguish the two tumor groups. As a strong correlation has been reported between AR mRNA copy number and AR protein abundance (20) , the 24 AR-underexpressing tumors would correspond to 'AR-negative' tumors in steroid-binding and immunohistochemical assays.
Overall, the results for AR-negative tumors in this study agree with those reported in the literature. The frequency (18%) of AR-negative tumors in our breast tumor series is similar to that obtained with steroid-binding and immunohistochemical assays (1, 4) . AR, PR and ERα expression were strongly intercorrelated, but we observed one AR-negative tumor that contained ERα (0.8% of our tumor series) and several AR-overexpressing tumours that did not contain ERα (5.3%), in keeping with others reports (1,4,21) . The negative association between AR and ERβ was probably due to the negative link between ERβ and ERα (data not shown). In addition to PR and ERα negativity, we found that AR gene underexpression was associated with SBR histopathological grade III but not with a poor prognosis, confirming that AR is more a marker of tumor aggressiveness (poorly differentiated tumors) than a predictor of patient outcome in breast cancer. As expected, we also found a correlation between AR underexpression and RB1 underexpression; indeed, in the same tumor series RB1 underexpression was also associated with poorly differentiated tumors (correlation with SBR histopathological grade III and PR and ERα negativity) (17) .
The 107 AR-positive tumors fell into two groups: those with normal AR expression (n ϭ 62) and those with AR overexpression (n ϭ 45). The amount of AR mRNA increased in tumors from both elderly and post-menopausal patients (Table III) , in agreement with Lea et al. (1) . This may be due to AR up-regulation to compensate for the decline in circulating sex steroids.
We observed a strong negative link between AR overexpression and MYC gene overexpression. No such link was observed between ERα (or ERβ) and MYC expression (data not shown). This study confirms the direct regulation of AR transcription by the c-myc transcriptor factor via a myc consensus site in an AR exonic region (22) and the downregulation of MYC mRNA associated with androgen-induced suppression of the transformed phenotype in the human prostate carcinoma cell line LNCaP (23) . No correlation was observed between AR overexpression and altered expression of the RB1, CCND1 and ERBB2 genes. This is in disagreement with previous data (24) (25) (26) , indicating that retinoblastoma protein, cyclin D1 and c-erbB2 control the transcriptional activity of AR, the latter regulating its own trancription.
We observed a positive correlation between AR and ARA70 expression, confirming the specificity of ARA70 in controlling transcription activity of AR in breast cancer, as in prostate cancer (27) . We did not observe a correlation between AR and DNMT1 expression, suggesting that the loss of AR expression in breast tumors is not due to up-regulation of DMNT1 via hypermethylation of the AR promoter CpG island. It is noteworthy that this finding does not exclude AR promoter methylation as a possible cause of AR down-regulation, due to modified expression of a DNA methyltransferase gene other than DMNT1. Finally, we found no link between AR status and PAP or PSA status. These two genes showed far lower expression levels than in prostate tissue, confirming the high specificity of PAP and PSA expression for prostate tissue.
In conclusion, our data suggest the involvement of several AR-mediated pathways in the regulation of breast tumor growth. Further characterization of these pathways may lead to new androgenic therapies for breast cancer.
Accurate determination of AR status, combined with ERα status, could help to select optimal endocrine therapies for breast cancer. The rapid, cost-effective, highly sensitive high throughput RT-PCR assay used here to determine AR status should be useful as a routine tool in AR-based clinical applications in breast cancer and other AR-related cancers.
